Anavex Life Sciences Corp (AVXL)

[falconer66a]

But I don’t make the mistake of so many.

I don’t presume that the future of Anavex 2-73 in any way parallels the numerous potential Alzheimer’s drugs that have failed in human trials. Importantly, virtually all of those have targeted end-stage outcomes of Alzheimer’s, primarily cellular wastes (beta-amyloids and tau tangles). If Anavex were aiming at eliminating those, I, too, would be extremely skeptical. Enough trials of various sorts — immunological, antibodies, etc. — have demonstrated that getting these out of neurons and nerves is extremely difficult, almost always with debilitating side effects, or insufficient efficacies.

This is where Anavex 2-73 is entirely different. Those accumulated cellular wastes, indeed, cause Alzheimer’s symptoms. Keep them from accumulating in neurons and nerves, or effectively and safely eliminate them after they are deposited, and Alzheimer’s symptoms abate. Both cellular and systemic homeostasis is restored.

Whatever the exact cause of the waste accumulations (most probably mis-folded waste-clearing enzymes), Anavex is effective because it fixes things at the start of the disease process, restoring normalized neuron functions so that, as in normal, non-diseased neurons or nerves, wastes are normally cleared. Keep the cell from malfunctioning at the start of the disease process, instead of trying to fix things after such malfunctions have been in place.

Apples and oranges. The many waste-targeting drugs have been apples, all rotten. Anavex 2-73 is a sweet, succulent orange, operating entirely differently (and more successfully) than any of the many previous waste-clearing trials. No comparison, once the underlying biochemical pathways in each approach are understood.